Novozymes Biopharma enters licensing agreement with EpiVax

Published: 6-Jan-2015
Research & Development

To advance treatments for autoimmune diseases


Novozymes Biopharma and EpiVax have entered a licensing agreement for the development of novel treatments for autoimmune diseases. The agreement follows two years of feasibility studies and allows EpiVax to use Novozymes’ albumin technologies to develop immunotherapies.

Novozymes will apply its Veltis technology to EpiVax’s Tregitope technology. Albumin works as a vehicle that transports the active drug ingredients throughout the body and increases the lifespan of the drug in the body to achieve improved patient compliance. As a result, it is possible to modulate half-life of a therapy to offer improved control, enhancing the overall efficacy of treatments.

'We are delighted to move into a licensing agreement with EpiVax in this key area of autoimmune diseases treatment,' said Peter Rosholm, Vice President of Novozymes Biopharma.

'In combination with the technologies and know-how EpiVax holds, Novozymes’ Veltis makes it possible to develop a potential “paradigm-shifting” treatment for autoimmune diseases.'

EpiVax has identified a set of natural peptide sequences, or epitopes, derived from Immunoglobulin G (IgG) that are potent activators of natural T regulatory cells (hence Tregitope). The initial application targeted by the Novozymes and Epivax collaboration will be the development of a recombinant alternative to intravenous immunoglobulin (IVIG) treatment.

'Novozymes’ proven solutions, technical expertise, and reputation as a reliable partner, makes it an ideal company for us to work with as we move our Tregitope immune-modulating technology even closer to clinical trials. After successful feasibility studies, we now move into the next phase, looking to develop a platform for immunomodulation that will change the way that we treat autoimmune diseases, allergy and transplantation,' added Annie De Groot, CEO/CSO of EpiVax.

  • Companies:
  • Novozymes
  • EpiVax
See more

You may also like

Research & Development

Protein properties project aims to guide development of new medicines

Read more
Four-year PIPPI project receives €4m in funding from Horizon 2020

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Precise and efficient VARIO diaphragm pumps from Vacuubrand Advanced vacuum control for reproducible processes
  3. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
  4. Bio-Courier: a new delivery technology to increase the global accessibility of RNA therapeutics Although lipid nanoparticles (LNPs) are a key delivery technology for nucleic acid therapeutics, their wider clinical translation is hindered by the recognised limitations of current manufacturing protocols
  5. Photocatalysed flow method accelerates synthesis of potent MC4R antagonist New automated continuous flow synthesis of spirocyclic tetrahydronaphthyridines for drug discovery

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Protein properties project aims to guide development of new medicines

Four-year PIPPI project receives €4m in funding from Horizon 2020
Research & Development

Novozymes Biopharma enters agreement with leading vaccine company

To conduct research on a novel subunit vaccine complex based on albumin fusion technology
Research & Development

Novozymes Biopharma to offer drug-albumin conjugation platform with ThioLogics

New partnership to offer serum-stable drug-albumin conjugation capability
Research & Development

Novozymes and Janssen to evaluate Veltis half-life extension technology

Series of engineered human albumins could help reduce dosing frequency of drugs
Research & Development

Novozymes Biopharma highlights potential for monthly drug dosing

New data findings demonstrate technological advances for extending serum half-life of drugs bound to albumin
Research & Development

Novozymes and EpiVax to develop autoimmune diseases treatment

Will combine Albufuse half-life extension platform with EpiVax Tregitope therapy
You need to be a subscriber to read this article.
Click here to find out more.
Design & Build

Quicker steps to chirals

Process chemistry groups within pharma companies are adept at solving chirality problems. To enable the practical synthesis of drug molecules for late stage trials and commercial production, they may apply reactions developed elsewhere or invent their own to create cheaper, more efficient and safer large-scale routes to chirally pure APIs
Subscribe now